AD 01 |
| Catalog No.GC50581 |
FKBPL(FK506-결합 단백질 유사)의 24개 아미노산 펩타이드인 AD 01은 강력한 항-혈관신생 활성을 보유합니다. AD 01은 CD44 수용체에 결합하고 CD44 의존적 방식으로 종양 세포 이동을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 959961-23-0
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
FKBPL (FK506-binding protein like)-based peptide. Binds to and upregulates expression of CD44. Inhibits breast cancer stem cell (BCSC) growth. Decreases pluripotency markers and promotes differentiation of BCSCs. Also inhibits endothelial cell migration as well as tubule and microvessel formation in vitro and in vivo. Blocks tumor growth in xenograft models.
Yakkundi et al (2013) The anti-migratory effects of FKBPL and its peptide derivative, AD-01: regulation of CD44 and the cytoskeletal pathway. PLoS One. 8 e55075 PMID:23457460 |McClements et al (2013) Targeting treatment-resistant breast cancer stem cells with FKBPL and its peptide derivative, AD-01, via the CD44 pathway. Clin.Cancer Res. 19 3881 PMID:23741069 |Valentine et al (2011) FKBPL and peptide derivatives: novel biological agents that inhibit angiogenesis by a CD44-dependent mechanism. Clin.Cancer Res 17 1044 PMID:21364036
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *